恒瑞医药(600276.SH)：HRS-2430注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Pharmaceutical has received approval from the National Medical Products Administration for the clinical trial of HRS-2430 injection, a new intravenous general anesthetic [1] Company Summary - HRS-2430 injection is positioned as a competitor to existing products such as etomidate, midazolam, and remimazolam [1] - The total global sales of etomidate, midazolam, and remimazolam are approximately $773 million for the year 2024 [1] - The cumulative R&D investment for the HRS-2430 injection project has reached approximately 24.6 million yuan [1]